Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Effectiveness · EFFECT

Traws Pharma, Inc.

Notice of Effectiveness

Filed Nov 12, 2026Accepted Nov 13, 2026, 12:15 AM ESTFiling CIK 1130598Accession 9999999995-26-003532
Share

Structured filing — EFFECT

primary_doc.xml

Open full document ↗

Notice details

Submission type
EFFECT
Act
33

Effectiveness

Effective date
2026-11-12
Effective time (as filed)
17:00:00
Form
S-1

Registrant 1

Registrant
Traws Pharma, Inc.
Registrant CIK
0001130598
File number
333-299644

Company context

Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to address real world challenges in the treatment of viral diseases. The Company is advancing novel investigational oral small molecule antiviral designed to have potent activity against difficult-to-treat or resistant virus strains. These include viruses associated with seasonal influenza and H5N1 bird flu, as well as negative-strand RNA viruses including Hantavirus, Ebola Virus Disease, and Lassa Fever and viruses associated with COVID-19/Long COVID.

Current securities

Historical securities (3)

Recent company filings

  1. 10-Q filingNov 16, 2026
  2. Results of Operations and Financial Condition · Regulation FD DisclosureNov 16, 2026
  3. 424B3 filingNov 16, 2026
  4. Regulation FD DisclosureNov 12, 2026
  5. D filingNov 5, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.